Handelsbanken Fonder
PTCT icon

Handelsbanken Fonder’s PTC Therapeutics PTCT Stock Holding History

Handelsbanken Fonder’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Buy
29,000
+3,800
+15% +$274K 0.01% 756
2026
Q1 		$1.72M Hold
25,200
– – 0.01% 802
2025
Q4 		$1.91M Sell
25,200
-2,900
-10% -$211K 0.01% 754
2025
Q3 		$1.72M Buy
28,100
+5,600
+25% +$292K 0.01% 782
2025
Q2 		$1.1M Sell
22,500
-1,300
-5% -$61.7K ﹤0.01% 919
2025
Q1 		$1.21M Hold
23,800
– – 0.01% 856
2024
Q4 		$1.07M Sell
23,800
-900
-4% -$38.5K ﹤0.01% 935
2024
Q3 		$916K Buy
24,700
+2,500
+11% +$83.7K ﹤0.01% 987
2024
Q2 		$679K Sell
22,200
-5,100
-19% -$165K ﹤0.01% 1017
2024
Q1 		$794K Buy
27,300
+10,600
+63% +$297K ﹤0.01% 943
2023
Q4 		$460K Buy
16,700
+3,400
+26% +$77.7K ﹤0.01% 1194
2023
Q3 		$298K Sell
13,300
-140,000
-91% -$5.21M ﹤0.01% 1310
2023
Q2 		$6.24M Sell
153,300
-38,700
-20% -$1.89M 0.03% 394
2023
Q1 		$9.3M Sell
192,000
-42,000
-18% -$1.92M 0.05% 338
2022
Q4 		$8.93M Sell
234,000
-271,400
-54% -$11.3M 0.06% 335
2022
Q3 		$25.4M Sell
505,400
-15,000
-3% -$735K 0.17% 151
2022
Q2 		$20.8M Buy
520,400
+141,400
+37% +$4.96M 0.14% 173
2022
Q1 		$14.1M Buy
379,000
+5,900
+2% +$227K 0.08% 243
2021
Q4 		$14.9M Hold
373,100
– – 0.07% 264
2021
Q3 		$13.9M Buy
373,100
+1,000
+0.3% +$41.1K 0.07% 265
2021
Q2 		$15.7M Buy
372,100
+1,300
+0.4% +$55.7K 0.08% 246
2021
Q1 		$17.6M Buy
370,800
+5,000
+1% +$297K 0.1% 203
2020
Q4 		$22.3M Sell
365,800
-11,000
-3% -$648K 0.14% 156
2020
Q3 		$17.6M Buy
376,800
+25,000
+7% +$1.23M 0.13% 166
2020
Q2 		$17.9M Buy
351,800
+29,800
+9% +$1.46M 0.15% 141
2020
Q1 		$14.4M Sell
322,000
-61,000
-16% -$3.07M 0.31% 90
2019
Q4 		$18.4M Buy
383,000
+60,000
+19% +$2.55M 0.32% 95
2019
Q3 		$10.9M Buy
323,000
+53,000
+20% +$2.31M 0.22% 114
2019
Q2 		$12.2M Buy
+270,000
New +$10.7M 0.22% 117

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Handelsbanken Fonder's PTCT Position: Q2 2026 in Review

Handelsbanken Fonder increased its PTC Therapeutics (PTCT) stake by 15% in Q2 2026, buying an estimated $274K and bringing the position to 29,000 shares worth $2.37M. The position accounts for 0.01% of the portfolio, ranked #756.

Handelsbanken Fonder first reported a position in PTCT in Q2 2019 and has held it in 29 quarters since. The position peaked at $25.4M in Q3 2022. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Handelsbanken Fonder held 29,000 shares of PTC Therapeutics worth $2.37M as of Q2 2026.
  • Handelsbanken Fonder bought 3,800 PTC Therapeutics shares in Q2 2026, an estimated $274K.
  • PTC Therapeutics made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #756 holding.
  • Handelsbanken Fonder first reported a position in PTC Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Handelsbanken Fonder's PTC Therapeutics position peaked at $25.4M in Q3 2022.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.